Tirzepatide

Details:

Tirzepatide (2023788-19-2) is Tirzepatide is a new type of drug for the treatment of type 2 diabetes, which is a combination of glucagon-like peptide-1 (GLP-1) receptor agonist.Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP, also known as: gastric inhibitory peptide) receptor and glucagon-like peptide-1 (GLP-1) receptor. Both GIP and GLP-1 are hormones secreted by the intestine and can promote insulin secretion. Tirzepatide combines two insulinotropic effects into a single molecule and represents a new class of drugs for the treatment of type 2 diabetes.

Applications:
Lowers blood sugar: Tirzepatide can promote the secretion and inhibit the secretion of glucagon, thereby effectively lowering blood sugar levels. In clinical trials, Tirzepatide showed more significant hypoglycemic effects than GLP-1 receptor agonists currently on the market.
Weight Loss: Tirzepatide has also shown significant weight loss effects. Because it suppresses appetite and increases satiety, it can help patients control their diet and reduce calorie intake, thereby achieving weight loss.
Reduces cardiovascular risk: Tirzepatide has also been shown in clinical trials to reduce the risk of cardiovascular events. This may be due to the combined effect of its ability to lower blood sugar, lower blood pressure, reduce weight, and other factors.